<DOC>
	<DOCNO>NCT02050321</DOCNO>
	<brief_summary>We propose conduct phase 2 study ass whether addition acitretin vemurafenib therapy able decrease rate cutaneous squamous cell carcinoma ( cSCC ) development , know side effect vemurafenib therapy , patient advance melanoma . Further , seek preliminary assessment whether addition acitretin vemurafenib enhance clinical efficacy anti-melanoma agent .</brief_summary>
	<brief_title>A Phase II Study Vemurafenib Combined With Acitretin Patients With Advanced Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Acitretin</mesh_term>
	<criteria>Histologically cytologically confirm advanced melanoma . BRAF mutation detect DNA sequence exon 15 . Age 18 old . ECOG Performance Status 02 . Appropriate tumor image study ( i.e . CT scan chest , abdomen pelvis PET/CT scan ) perform within 28 day study registration . Patients melanoma measurable RECIST 1.1 criterion monitor use system evidence disease response/progression . Patients known history brain metastasis must diagnostic quality MRI brain contrast CT scan head perform within 28 day prior registration . Female patient child bear capacity must 2 negative urine serum pregnancy test sensitivity least 25 mIU/mL receive initial acitretin prescription . The first test ( screen test ) obtain prescriber decision make pursue acitretin therapy . The second pregnancy test ( confirmation test ) do first 5 day menstrual period immediately precede begin acitretin therapy . The second test need repeat perform within 14 day prior registration . Willingness use least two form contraception sexual intercourse , include least one form barrier contraception , least 30 day prior receive first dose acitretin AND study period , AND 3 year receive last dose acitretin . Patients must agree consume alcoholic beverage receive acitretin 2 month cessation therapy . Electrocardiogram QTc &lt; 450 ms baseline . Patients must evaluate follow within 14 day prior registration : leukocytes &gt; 3,000/mcL absolute neutrophil count &gt; 1,500/mcL platelet &gt; 100,000/mcL Hemoglobin &gt; 9.0 g/dL AST ( SGOT ) /ALT ( SGPT ) &lt; 2.5 X institutional upper limit normal Alkaline phosphatase &lt; 2.5 X institutional upper limit normal Total bilirubin &lt; 1.5 X institutional upper limit normal Renal function serum creatinine &lt; 1.5 mg/dL OR 1.5 x institutional normal ; alternatively , creatinine clearance assess 24hour urine collection â‰¥60 ml/min Total cholesterol &lt; 239 mg/dL &lt; 6.1 mmol/L LDL &lt; 159 mg/d &lt; 4.1mmol/L HDL &gt; 40 mg/dL &gt; 1.0 mmol/L Serum triglycerides &lt; 199 mg/dL &lt; 2.2 mmol/L Potassium 3.55.5 mMol/L Magnesium 1.72.6mg/dL Calcium 8.510.6 mg/dL Known hypersensitivity vemurafenib , acitretin , vitamin A analogue . Uncontrolled hypertension . Serious uncontrolled hypertriglyceridemia . Uncontrolled coronary artery disease active anginal symptom . Uncontrolled brain metastasis . Concomitant malignancies previous malignancy within last 5 year , exception adequately treat basal squamous cell carcinoma skin , carcinoma situ cervix , lowgrade prostate cancer . Myocardial Infarction , Transient Ischemic Attack ( TIA ) , Cerebrovascular Accident ( CVA ) symptomatic Congestive Heart Failure ( CHF ) within 6 month study registration . Corrected QTc interval &gt; 450ms baseline , history congenital long QT syndrome , know uncorrectable electrolyte abnormality . History organ hematologic transplant . Underlying defined genetic syndrome base individual family history predispose high risk nonmelanoma melanoma skin cancer assess treat Oncologist . Concurrent use St John 's Wort . Concurrent ( within 60 day prior acitretin dose ) use methotrexate tetracycline , phenytoin , vitamin A supplement , Tegison ( etretinate ) progestinonly oral contraceptive . Pregnant nursing . Receipt investigational agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>